-
-
-
-
-
-
-
Vanda gets FDA extension for tradipitant motion sickness drug review
-
-
-
-
-
-
-
Vanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
-
-
-
-
-
-
-
Future Pak Increases Bid for Vanda Pharmaceuticals (VNDA) to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash
-
-
-
-
-
-
-
Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Cli
-
-
-
-
-
-
-
Vanda Pharmaceuticals (VNDA) Applications for HETLIOZ Accepted by FDA for Priority Review
-
-
-
-
-
-
-
Vanda (VNDA) Announces FDA Accepts HETLIOZ sNDA for Review in Treatment of Jet Lag Disorder
-
-
-
-
-
-
15,435 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

